CINRYZE 500
Phase 3Biologic
TakedaCINRYZE 500 is one of 46 biologic programs targeting Angioedema. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
43 competitors in Hereditary Angioedema
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Crestor
AstraZenecaApproved
Firazyr
TakedaPhase 3
Lanoxin
AAdvanz Pharma
Approved
Andembry
CSL BehringApproved
Cyklokapron
AAmring
Phase 3
KALBITOR
TakedaPhase 3
C1 Esterase Inhibitor
TakedaPhase 3
Dawnzera (autoinjector)
Ionis PharmaceuticalsPhase 3
Ruconest
PPharming Technologies B.V.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hereditary Angioedema2 trials
Angioedema1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CINRYZE 500. EMBL-EBI & Wellcome Sanger Institute.
- [4]